PharmaCyte Biotech (Formerly Known As Nuvilex)
1971 Old Cuthbert Road
Cherry Hill
New Jersey
08034
United States
Tel: 856-433-6088
Fax: 856-354-1077
Website: http://www.nuvilex.com/
Email: info@nuvilex.com
375 articles about PharmaCyte Biotech (Formerly Known As Nuvilex)
-
PharmaCyte Biotech Enters into License Agreement for COVID-19 Diagnostic Kits
4/8/2020
PharmaCyte Biotech, Inc. announced today that it entered into a License Agreement (Agreement) with Hai Kang Life Corporation Limited, a corporation organized under the laws of Hong Kong (Hai Kang), pursuant to which Hai Kang granted to Pharm
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
-
PharmaCyte Biotech Addresses Submission of IND and Recent FDA-Required Testing
3/12/2020
PharmaCyte Biotech, Inc. announced the latest in its series of Q&A articles that are conducted with some of the key management members of PharmaCyte’s research and development team related to its upcoming clinical trial in locally advanced, inoperable pancreatic cancer.
-
PharmaCyte Biotech Receives Certificates of Analysis and Batch Records for its Clinical Trial Product in Pancreatic Cancer
2/12/2020
Feb. 12, 2020 14:00 UTC LAGUNA HILLS, Calif.--( BUSINESS WIRE )-- PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has received the Certificates of Analysis and the records from both batches of its clinical trial product manufactured by Austrianova Singapore (Austrianova). As previously reported, both batc
-
PharmaCyte Biotech Successfully Completes All Release Tests on Clinical Trial Product
1/22/2020
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that both batches of the company’s manufactured clinical trial product have undergone and passed all 10 of the necessary “release tests” required by the U.S. Food and Drug Administration (FDA).
-
PharmaCyte Biotech Passing All Completed Tests on Clinical Trial Product
12/23/2019
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that both batches of the company’s manufactured clinical trial product have now passed 7 of the 10 completed “release tests” per batch required by the U.S. Food and Drug Administration (FDA), including the test for “enzymatic activity” on both batches.
-
PharmaCyte Biotech Provides Details on Quarterly Shareholder Update
12/19/2019
The company’s resources are fully engaged in completing its 10-Q for the period ending October 31, 2019 and are being dedicated to submitting its Investigational New Drug application (IND) as quickly and correctly as possible.
-
PharmaCyte Biotech to Hold Quarterly Shareholder Update
12/10/2019
The update will include the latest information available on preparing to submit an Investigational New Drug application (IND) to the U.S. Food and Drug Administration, a review of the company’s activities during the quarter, and a Q&A period to answer any questions that shareholders may have.
-
PharmaCyte Biotech “Release Testing” Successful on All Completed Tests of Clinical Trial Product
11/25/2019
PharmaCyte Biotech, Inc. (OTCQB: PMCB), announced today an update on the completed tests that are part of the U.S. Food and Drug Administration (FDA) required “release testing” related to the company's first manufactured batch of its clinical trial product to be used in its planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).
-
PharmaCyte Biotech Successfully Completes Final Manufacturing Run of Clinical Trial Product
11/18/2019
The capsules, which are fully filled with genetically modified live cells, were immediately put into PharmaCyte’s clinical trial syringes and then frozen.
-
PharmaCyte Biotech Closer to Submitting IND by Successfully Completing Encapsulation of Second Manufacturing Run of Clinical Trial Product
11/4/2019
This product will be used for PharmaCyte’s planned clinical trial in patients with locally advanced, inoperable pancreatic cancer
-
PharmaCyte Biotech Q&A Discussion with Cellular Biologist David A. Judd
10/1/2019
PharmaCyte Biotech, Inc. announced the latest in its series of Q&A articles that are conducted with some of the key team members of PharmaCyte’s research and development program related to its upcoming clinical trial in locally advanced, inoperable pancreatic cancer.
-
PharmaCyte Biotech Releases Shareholder Update Call Playback Information
9/25/2019
An audio recording of the company’s shareholder update call, which was held on September 20, 2019, by PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, is now available for playback.
-
PharmaCyte Biotech Provides Information on Upcoming Shareholder Update Call
9/16/2019
The call is scheduled for Friday, September 20, 2019, commencing at 4:00 p.m. Eastern Daylight Time. The telephone number for the call is (515) 604-9056. The access code for the call is 195-864.
-
PharmaCyte Biotech Releases Results of Shareholder Meeting and Provides Information on Upcoming Shareholder Update Call
9/12/2019
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the results of the Special Shareholder Meeting and provides information on the shareholder update conference call scheduled for next week.
-
PharmaCyte Biotech Holding Special Shareholder Meeting Today
9/11/2019
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced a reminder for shareholders that this morning a Special Shareholder Meeting will take place at the Courtyard Irvine Spectrum in Irvine, California, and will begin at 11:00 a.m. local time.
-
PharmaCyte Biotech Releases New Video Documentary of Its Pancreatic Cancer Treatment
9/4/2019
The video was written and produced by Stock Market Media Group
-
PharmaCyte Biotech Confirms Dr. Manuel Hidalgo Will Be Principal Investigator for Clinical Trial in Pancreatic Cancer
8/28/2019
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that nationally and internationally renowned clinician and oncologist, Dr. Manuel Hidalgo, has confirmed that he will be Principal Investigator (PI) for PharmaCyte’s planned clinical trial
-
PharmaCyte Biotech Releases Proxy Statement Related to Special Shareholder Meeting
8/27/2019
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its proxy statement related to the announced Special Shareholder Meeting on September 11, 2019, is available on PharmaCyte’s website at: https://ir.pharmacytebiotech.com/proxy.
-
PharmaCyte Biotech to Hold Special Shareholder Meeting
8/21/2019
The shareholder meeting, not to be confused with a shareholder conference call, will be held at the Courtyard by Marriott in Irvine, California, and will begin at 11:00 a.m. Pacific Daylight Time.